CA2110716C - Optical cerebral oximeter - Google Patents
Optical cerebral oximeter Download PDFInfo
- Publication number
- CA2110716C CA2110716C CA002110716A CA2110716A CA2110716C CA 2110716 C CA2110716 C CA 2110716C CA 002110716 A CA002110716 A CA 002110716A CA 2110716 A CA2110716 A CA 2110716A CA 2110716 C CA2110716 C CA 2110716C
- Authority
- CA
- Canada
- Prior art keywords
- brain
- signals
- blood
- readout
- location
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002490 cerebral effect Effects 0.000 title claims abstract description 46
- 230000003287 optical effect Effects 0.000 title claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 43
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 43
- 239000001301 oxygen Substances 0.000 claims abstract description 43
- 108010054147 Hemoglobins Proteins 0.000 claims abstract description 32
- 102000001554 Hemoglobins Human genes 0.000 claims abstract description 32
- 239000008280 blood Substances 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 210000003625 skull Anatomy 0.000 claims abstract description 11
- 230000036770 blood supply Effects 0.000 claims abstract description 9
- 239000002131 composite material Substances 0.000 claims abstract description 5
- 210000004556 brain Anatomy 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 35
- 238000012545 processing Methods 0.000 claims description 17
- 238000001228 spectrum Methods 0.000 claims description 17
- 238000001727 in vivo Methods 0.000 claims description 13
- 238000006213 oxygenation reaction Methods 0.000 claims description 8
- 210000004761 scalp Anatomy 0.000 claims description 8
- 238000002798 spectrophotometry method Methods 0.000 claims description 7
- 210000003128 head Anatomy 0.000 claims description 5
- 210000005166 vasculature Anatomy 0.000 claims description 4
- 230000000007 visual effect Effects 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 abstract description 7
- 230000005670 electromagnetic radiation Effects 0.000 abstract 1
- 210000001061 forehead Anatomy 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 18
- 238000005259 measurement Methods 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 10
- 230000006870 function Effects 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 239000000700 radioactive tracer Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000004783 oxidative metabolism Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 230000008033 biological extinction Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000004020 conductor Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 108010064719 Oxyhemoglobins Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 108010002255 deoxyhemoglobin Proteins 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000002496 oximetry Methods 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008321 arterial blood flow Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 238000013172 carotid endarterectomy Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14552—Details of sensors specially adapted therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
- A61B5/02427—Details of sensor
- A61B5/02433—Details of sensor for infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
- A61B5/14551—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases
- A61B5/14553—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters for measuring blood gases specially adapted for cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4058—Detecting, measuring or recording for evaluating the nervous system for evaluating the central nervous system
- A61B5/4064—Evaluating the brain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Neurology (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
A cerebral oximeter for use with a sensor unit (12) applied to the fore-head of a patient, or other such selected cranial area, whihe emits selected wave-lengths of electromagnetic radiation (e.g. light in the near infrared range) that passes through a selected volume of brain tissue in-side the patient's skull. The emitted wavelengths are se-lectively absorbed by the blood within the irradiated brain tissues, present in ar-terial, venous, capillary, and/or other supply, and the resulting radiation is detected and analyzed by a computer (20) to determine the hemoglobin oxygen sat-uration of the composite blood supply within the se-lected volume of brain tis-sue, with readout provided as a quantified particular value (e.g., a number representing the instantaneous value measured), and/
or also in graphical or other time-representative display, as far example on the CRT monitor (22) of the computer, with attendant storage of digital values for record purposes or other subsequent use.
or also in graphical or other time-representative display, as far example on the CRT monitor (22) of the computer, with attendant storage of digital values for record purposes or other subsequent use.
Description
W~ 92t21283 2 - . ~ ~ ~ PCT/U592/44654 OPTICAL CEREBRAL OXIMETER
TECHNICAL FIELD
This invention relates generally to in vivo spectrophotometric methods and apparatus, for examining and/or monitoring biological tissue, substances and/or conditions in living subjects, in particular humans.
More particularly, the invention relates to the novel application of such in vivo methods and apparatus to provide a new form of biomedical device for non-invasively monitoring oxidative metabolism in mammalian (e.g. human) subjects on an in vivo basis, a specific and preferred embodiment of which comprises means for so-monitoring regional oxygen saturation in the brain, and for providing a quantitative readout thereof in terms familiar tee medical practitioners, i.e., percent oxygen saturation.
BACKGROUND
Bpectrophotometry has, of course, long been used as a valuable investigative tool in various scientific fields, particularly biological and medical research, and various applications of the underlying principles utilizing selected wavelengths of light in the near infrared range (often referred to as N.I.R.
spectrophotometry) have for quite some time been utilized for certain in vivo procedures and/or investigation on human beings. For example, a frequently-encountered such device is the pulse oximeter conventionally used in hospitals and other medical facilities to provide a direct indication of arterial oxygen saturation by means of a clip or the like which fastens to an appendage such as the ear or finger of the patient. As has been noted by a small but growing field of investigators, the potentialTy~useful applications of N.I.R. in vivo spectrophotometry are considerably broader and more diverse than this, however, due to the interesting and ' useful characteristic of ?t.I.R. wavelengths in being able to pass through ("transmiss") biological substance such as human skin, bone, and tissue for at least a length of several centimeters, and a useful: brief description and WAD 92/21283 ~ 11 p '~ ~ ~ PCT/US92104654 commentary as to this is set forth in patents attribut-able in at least part to the present inventor (see for example U.S. Patent No. 4,570,638j, as well as in the various references of record therein. In the latter regard, particular reference is made to the patents issued to Jobsis et al, e.g. U.S. Patents Nos. 4,281,645, .4,223,680 and 4,321,930.
While previous developments in the general field of N.I.R. in vivo spectrophotometry, as noted above, have no doubt provided interesting and at least potentially useful insights and information heretofore, many important,further developments and applications no doubt remain to be made, and certain of these are likely to be of considerable importance~to medical practitioners. For example, accurate, meaningful, non-intrusive monitoring of brain status and viability is a most important need which prior technology has not sufficiently satisfied.
As is well known and widely appreciated, the brain is a delicate and easily-damaged portion of human anatomy, while at the same time being the epicenter of neurological and physiological function. Brain damage through injury or cerebral vascular disease is responsi-ble for numerous deaths and serious illnesses each year, involving on the order of at least 100,000 surgical procedures annually in recent years. Brain vitality is primarily a function of oxidative metabolism, and the pres~ominant cause of neurological dysfunction and w malfunction relates to the lack of sufficient brain oxidation, typically as a result of obstruction or othex~rise insufficient arterial blood flow to the brain.
Of course, this can occur even during surgery, and it has been estimated that at least 2,000 patients die each year in the United States alone due to anesthetic accidents, while numerous other such incidents result in brain damage of some degree; at the same time, certain major and complex surgical procedures, particularly of a neurological, cardiac or vascular nature, may require induced low blood flow or pressure conditions, which W~ 92/2~2~3 ~ PCTlUS92/fl46S4 inevitably involves the potential of insufficient oxygen delivery to the brain. At the same time, the brain is the human organ which is most intolerant of oxygen deprivation, and brain cells will die within a few minutes if not sufficiently oxygenated. Moreover, such cells are not replaced, and thus involve irreversible -brain damage which may potentially result in paralysis, disability, or even death.
Accordingly, the availability of immediate and accurate information concerning the state of brain oxygen saturation is of critical importance to anesthesiologists and surgeons, as well:as other involved medical practi-a tioners, particularly since the patients involved are typically in an unconscious state and thus unable to-provide information by ordinary physical response. Up until the present time, however, the instrumentalities available for use, including such things as electroencephalograph ("EEG"), arterial pulse oximeter and blood pressure monitors, etc., and even invasive catheter monitoring of blood oxygen content, acidity, etc. by penetration of the jugular bulb (jugular vein) do not provide accurate, ongoing, timely (instantaneous) information as to cerebral (brain) blood oxygenation state, particularly since the brain blood supply is extensive, diffuse, pervasive, and largely venous in nature rather then arterial. Of course, it is also thus devoid of conventional pulsative characteristics essen-' tial to the operation of conventional oximeters.
Accordingly, such devices are not appropriate for cerebral usage, and of course they are typically made to be applied only to peripheral tissue or appendages in any event, i.e...~ a finger or an ear lobe, and are not utilized in conjunction with venous blood. Of course, jugular bulb catheters are highly invasive and relatively traumatic: at the same time, they merely provide blood samples which are removed and analyzed in another location, at a subser~uent point in time, and thus only WO 92/2123 ~ ~~ ~ PCT/US92/04~54 address the state of venous blood after it has left the brain.
BRIEF SUM~~ARY OF INVENTION
In a specific and particular sense, the present invention provides a spectrophotometric cerebral oximeter, which non-invasively and harmlessly provides -accurate and continuous real-time information as to the oxygenation state of the human brain, on an in vivo basis, without attendant patient stress or discomfort of any nature. More broadly considered, the present invention provides in vivo spectrophotometric methods and apparatus adaptable to other relatively analogous biomedical procedures and functions, for monitoring oxidative metabolism and/or other physiologic function, condition, or state.
In the particular preferred embodiment disclosed, the invention provides an in vivo, spectrophotometric cerebral oximeter which will non-invasively provide continuous monitoring of cerebral oxidation, and will do so in a form and format of a nature immediately under-standable and familiar to physicians, i.e., percent oxygen saturation. Further, the cerebral oximeter so provided operates by examining (sampling) the cerebral blood supply throughout the complete vascularization (arterial, venous, and capillary systems) within the area of investigation, and the particular region investigated is or may be selectively accessed in accordance with the invention, i.e., the tissue volume examined is regional in nature and of a generally predetermined extent and location, constituting less than the entire brain or other area. Still further, the apparatus and methodology in accordan,~e with the invention includes the provision of a convenient and readily-usable sensor which may for example be used in a number of different locations, and/or moved from one location to another, for compara-tive consideration of the regions selectively accessed and examined, whether cranial or otherwise.
VV~ 92/21283 PCi'/U~92/t~46S4 _5_ Accordingly, the cerebral oximeter in accordance with the invention examines, and measures, blood oxygen saturation (and thus, oxidative metabolism) in the entire array of blood vessels present in the cranial region being monitored, which in the brain may generally be considered as comprising (by volume) approximately 75 -percent venous, 20 percent arterial, and 5 percent capillary. Thus, the cerebral oximeter provided in accordance with the invention addresses not only oxygen delivery via hemoglobin molecules moved arterially, but in addition addresses the general, overall state of cerebral oxygen consumption, which is of course directly ralated to brain vitality and state, and indicative of continued viability. As already indieated, the invention provides such information on an instantaneous real-time basis, and as a result provides critical immediate information capable of clearly and quantitatively indicating the need for urgent measures to provide increased or decreased cerebral oxygen supply or consumption (metabolic activity), momentary responses to which may well prevent serious neurologit~al or other trauma or injury.
In addition, the cerebral oximeter or other such apparatus provided in accordance with the invention is convenient to use, non-invasive and non-traumatic, produces no attendant side effects, and provides specific, quantified information of a type not previously available. At the same time, such apparatus is compact and relatively portable in nature, may provide direct visible monitoring vii CRT or other visual display, and provides digitally storable data which may readily be maintainec't~,~or future review or comparison or printed out in hard copy, plotted, etc., and/or periodically accessed to provide ongoing trend data, for displaying or analyzing changes which occur over selected periods of time. As such, the apparatus may be used in such diverse circumstances as emergency or trauma conditio::.~, whether in the field (at the scene of accidents, etc. ,nor WO 9212~2~3 Pf.'T/US92/~654 example) or in emergency medical centers, intensive care units, surgical operating rooms, hospital trauma centers, or at bedside, etc. In particular, however, use during ongoing surgical procedures is clearly anticipated as satisfying an existing and important medical need, particularly during such procedures as brain surgery, . open heart, organ or other transplant surgery, or that involving major blood vessels, for example, carotid endarterectomy; or other bypass surgery, etc., where blood flow is maintained through heart-lung machines and there is no arterial pulse present at all in the braiw or body.. a ..:. : ::. ::
The".foregoing major objectives;'advantages and considerations of the invention, together with and including others, will become more apparent following consideration of the ensuing specification, particularly taken in conjunction with the appended drawings, briefly described hereinafter. Once again it is pointed out that the apparatus and methodology principally described hereinafter constitutes merely a preferred embodiment of the underlying invention, and does not specifically address other and further aspects thereof which will or may become further appreciated by those skilled in the art after consideration of the overall disclosure herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a pictorial schematic representation simplistically showing the basic application and utiliza-tion of apparatus in accordance with the invention:
Fig. 2 is a further pictorial schematic representa-tion somewhat similar to Fig. 1 showing additional aspects of the subject matter disclosed;
Fig.. 3;'is an end view of a first optical sensor assembly for use in conjunction with the invention;
Fig. 4 is a pictorial side view representation of a different form of optical sensor, of a more preferred nature;
2~~~'~ 1~J
WO 92/2I2~3 PCT/US92/0465~
Fig. 5 is a schematic representation depicting the regional examination of the head and brain in accordance with the invention:
Fig. 6 is a graphical representation illustrating the spectral absorption characteristics of hemoglobin;
Fig. 7 is a graphical representation showing _ measured cerebral hemoglobin oxygen saturation in accordance with the invention in a first test subject;
Fig. 8 is a graphical representation showing measured cerebral hemoglobin oxygen saturation in accordance with the invention in a second test subject;
Fig. 9 is a graphical representation showing cerebral vaseular oxygenation activity contrasted with extracerebral oxygenation~of the scalp and skull, as measured by the near and far detectors provided in the sensor assembly utilized by the invention: and Fig. 10 is a further graphical representation showing cerebral oximetry measurements in accordance with the invention.
DESCRIPTION OF PREFERRED EMBODIMENTS
Oxygen is supplied to the brain by hemoglobin molecules contained-in the blood supply, to which the oxygen molecules become bonded during the oxygenation process which occurs in the lungs as the blood is pumped by the heart through arteries and capillaries to the brain. As previously stated, the brain extracts oxygen from the hemoglobin by oxidative metabolism, and resulting carbon dioxide molecules are carried away through the capillaries and veins to the lungs for reoxygenation. Generally speaking, the optical spectrophotometry utilized by the invention is based upon the seler~tive attenuation of particular light spectra in the near infrared range which is exhibited by oxygenated hemoglobin as compared to reduced (deoxygenated) hemoglobin contained in the blood present within the cerebral region under examination. Figs. 1 and 2 pictorially and schematically show the overall or general application.of the apparatus and methodology of the invention to the human cerebrum. Thus, Figs. 1 and 2 show a human subject 10 upon whom apparatus in accordance with the invention is being utilized, such apparatus comprising a sensor means 12 for applying and receiving selected light spectra to a particular region 14 of the brain through or via conductors 16 (which, as subsequently noted, may be electrical or optical in nature), from or in conjunction with an infrared spectrophotometry unit 18 which includes in part a small digital computer 20 having a monitor 22 on which various forms of readout information may be presented. As generally shown in a pictorial and schematic manner by Fig. 2, the sensor. assembly 12 applies selected light wavelengths which may emanate from a broadband source 24 (e. g., an incandescent lamp) and be selectively determined by narrow-bandwidth (monochromatico) filters 26, although as subsequently noted a preferred embodiment utilizes dedicated light-emitting diodes ("L.E.D.s") which produce the selected light spectra, and the computer 20 generally includes an A/D converter section 28, control circuitry 30 (depicted as a circuit board configured to mount in the expansion slats of computer 20), together with requisite computer memory 32 and an operator control in the form of a keyboard 34.
The sensor assembly 12 may as a general matter be in accordance with one embodiment that is shown for example in Fig. 3. It may be noted that, as shown in Fig. 3, such a sensor assembly 12' generally comprises a housing or other support 36 which carries a light-emitting element 38, a first light-detector or receiver 40 (i.e., the " near " receiver) and a second such detector or receiver 42 (the "far " receiver) which is disposed a predetermined and particular distance away from the source 38 and the " near " receiver 40. In the ,ii -g-sensor assembly 12" is more elongated in overall shape and preferably has a somewhat flexible support 136 which carries the light source 138 and the near and far receivers 140, 142, respectively, all arranged in a longitudinal array, disposed along a common linear axis.
It may be noted that in this preferred form the source 138 comprises a pair of separate (but commonly-mounted} light-emitted diodes which provide at least two particularly-selected wavelengths (described in more detail subsequently herein), and the receivers 140 and 142 comprise photodivdes. As a result, the entire sensor assembly 12" is relatively small and compact, lightweight, and thin, as well as being at least modestly flexible; of course in this form the conductor array 16' comprises electrical conductors, since the operative elements are electro-optical emitters and detectors. Of course, such components operate with very low levels of , electrical excitation, and the actual conductors 16' are each insulated from one another and carried within an insulating outer sheath 116.
Regardless of the particular form of sensor assembly 12 which is utilized, the inclusion and relative spacing of the source 38, 138, near receiver 40, 140, and far receiver 42, 142 are of importance to the proper function and performance of apparatus. in accordance with the invention.
In general, however, the near receiver (40, 140) is close to but spaced a particular distance from the source (38, 138) so that the photons (light energy) which it detects in ,: , , 11 ~ '~ .1 f;
WO 92!21283 PCTIL'S92/046~4 response to the emission of selected light spectra by the source will traverse primarily only the skin (scalp) and bone ( skul l ) of the subj ect 10 , whereas the °' far"
receiver (42, 142) is disposed a particular further distance from the source whereby the light energy (photons) which it receives samples a deeper tissue volume comprising primarily brain tissue. This selected brain tissue volume which is sampled, as generally delineated by the curving line designated 114 which illustratively depicts the mean optical path of the photons received at the far receiver 42, 142, constitutes the selected region 14 noted previously (Fig:el), and it will be~observed that such region constitutes a particu~
lar internal volume within the overalllbrain content whose location is determined by the relative disposition and separation of the source 38, 138, near receiver 40, 140, and far receiver 42, 142, together with the relative placement and location of the sensor assembly 12 upon the head of the subject 10.
Of course, there are practical limits to the maximum distance at which the far receiver (40, 140) may be disposed relative to the source (38, 138), since the level of light energy used must be less than that which would be harmful, while at the same time there must be more than merely trivial amounts of light energy received at the far receiver, in order to obtain meaningful data from the spectral modulation or attenuation of the light by the substance transmissed. As presently envisioned, it is probably not effective or useful to dispose the far receiver directly opposite (across the entire skull width) from the source, by which the complete width or diameter o-f,'the brain is transmissed, and it will be noted that in the configurations discussed above and depicted in the drawings, both the near and far receivers operate more in a "reflectance" mode than a "transmission" mode as those terms are conventionally used (i.e., they are disposed along mean optical paths 'which are curved, and_are relatively close to the i source). Of course, as already indicated, this is directly consistent with monitoring regional brain function, which represents the preferred embodiment of the invention. By way of example, in a particular such preferred embodiment the distance between the source and near receiver is approximately 0.3 inches, while the distance between the source and far receiver is approxi-mately 1,0 inches.
Generally speaking, some of the basic principles underlying the invention may be appreciated by reference to Fig. 6, which shows the known absorbtivity of hemoglobin to selected N.I.R. light wavelengths. As there illustrated, the spectral absorption characteris-tics of oxygenated hemoglobin describe a family of curves which intersect, and reverse, at a wavelength of approxi-mately 800 nanometers ("nm"), which constitutes the isobestic point (typically considered to be at 815 nm).
As illustrated, the absorbtivity of reduced (deoxygenated) hemoglobin rises progressively at lower wavelengths as a function of the relative absence of oxygen, the highest such curve thus rep resenting fully deoxygenated hemoglobin and the lowermost such curve representing fully oxygen-saturated hemoglobin. As shown, these curves describe a peak in the general range of about 760 nm, as well as a valley or dip at approxi-mately 730-740 nm. Accordingly, as is already known, by monitoring the optical response at selected wavelengths, i.e., by comparing intensity of light received at wavelengths less than the isobestic point with that received at the latter, and making appropriate computa-tions, the oxygen content of sampled hemoglobin may be determined. In accordance with the invention, such sampling is preferably carried out at wavelengths representing points of most gradual change, rather than WO 32!21283 ~ ''~ ~ ~ PCTlUS92l04654 points representing steepest slopes: accordingly, a first sampling wavelength may be in the range of about 735 nm, and another may be at approximately 760 nm. Since the specific point at which isobestic conditions exist may vary somewhat as a result of a number of factors, the reference wavelength is preferably selected to be at approximately 805 nm.
In view of the foregoing, it will be appreciated that the primary focus of this description of preferred embodiments is based upon N.I.R. spectrophotometric procedures directed toward measurement: of oxyhemoglobin and deoxyhemoglobin, in order to provide a cerebral .:
oximeter as..noted,:above, i.e., an apparatus for providing quantified information as to regional oxygen saturation in the composite vasculature of the brain, and the following further description sets forth mathematical descriptions and characterizations of the underlying rationale and procedure for such a device. It should be expressly noted, however, that the underlying invention is not necessarily limited to this specific application, and indeed is believed to have direct or meaningful application to other in vivo procedures which are or may be primarily attributed to or defined in meaningful part by other well-characterized chromophores, particularly (but not necessarily) in other somewhat analogous regional areas or domains, where information relative to biological processes in such a reasonably defined and distinctive area is important, and it is necessary or useful that such information be free of distortions attributable to hemoglobin or other attributes character-izing the satin, bone, and dura which is superficial to the more deeply-located region to be investigated.
With further and continuing reference to the particular preferred embodiment under discussion, it will be appreciated that the methodology of the invention utilizes diffused near-infrared spectroscopic procedures of a generally transmission-mode character for quantita-tive evaluation of tissue which is highly scattering and i~~ 92/21283 ' ~ ~ 6 PCT/US92/0~651t partially absorptive in nature, utilizing spatial resolution for region definition. Since wavelength-specific attenuation of light propagated through such tissue is a function of the chromophores, their extinction coefficients, their concentrations, and the distance photons travel in the tissue, the basic relationship may be analogized too, and expressed in accordance with, the Beer-Lambert relationship as set forth below, even though this is in fact deemed specifi-cally descriptive of homogeneous non-scattering media:
Itw> '~ It~~e In the foregoing expression, the quantity I(w) represents intensity of transmitted light at wavelength w, the term I(w)0 represents the intensity of the inci-dent light at wavelength w, the term a represents the molar extinction coefficient of the light-absorbing mol~cul~ (chromophore), the term C represents the content of such chromophore in the tissue under examination, and the term s represents the photon pathlength in the tissue of interest. By use of this relationship, a fundamental approximation is obtained for interpreting the N.I.R.
spectra utilized; since there are at Least three signifi-cant chromophores present in brain tissue, each with separate extinction coefficients and concentrations, the above-noted relationship may be modified and expressed as follows:
N
~~~ yw~iwb ~ ~ aiw, ~l~ys The measurements made at the selected examination wavelengths may be usefully referenced by subtracting them from referenced measurements made at second selected wavelength i.e., the isobestic point of hemoglobin noted above in connection with Fig. 6. Since the above relationship refers to absorption at wavelength w, absorption at a s~cond wavelength w' is subtracted from WO 92/2123 ~ ~ ~ ~ l ~ ~j PCT/U~~2/04g54 °14°
that at the first wavelength, w, yielding the following expressions ~ ~g~rzw~~r ~ ~c~~. 3'~ ~ ~~'. jl~'(i)~
~1 The foregoing expression may be simplified by use of arbitrary definitions; 1.e., everything directly measured may be defined by the variable M. Since the difference in extinction coefficient is also a known, it may be defined by the tens d. Accordingly:
c,~> ~ ° c~;~c~~ + 1~ I~~t~cW~~
c~. ;~ ' ~c.~, ;) ~ ~c~~. ;~
Thus, the expression describing absorption at a second wavelength w' subtracted from that at a first wavelength w may be reduced to the following simpler notation:
~ ~ dc.., ,7Cci~s s Consideration of the simplified relationship dust express~d reveals that the variable of interest, ~chromophore concentration, may be quantified for oxyh~raoglobin and deoxyhemoglobin if such expression is solved by making (N+1) measurements of M to solve for C(p)s (oxyhemogolbin) and C(p)s (deoxyhemogolbin) independently. These values are proportional to chromophore content. The value s is a constant, and by i~~ 92/212$3 2 ~ ~ PCT/1J~92/04fi54 calculating the ratio of deoxy- to oxy- hemoglobin, this constant cancels out of the expression. If this is assumed to be constant, the number of unknowns does not increase subsequent measurements, and this assumption appears to be well-supported. Thus:
C~.r~~~ _ ~c~.~Cc~ ~ I-i~
In the foregoing expression, the variable fir represents the hemoglobin ratio of deoxy- to oxyhemoglobin, which raay then be used to solve for the r~gional saturati~n of hemoglobin designated rSHgbo2 below:
1!( 1 + ) _ ~( ~. s) ~ r~I~ ' B
It will therefore be se~n that the term "rSFigboa", defined as "regional saturation of hemoglobin", constitutes the ratio of oxygenated hemoglobin to total hemoglobin in the sampled field (defined region) of the brain under investigation. As previously stated, this region will contain both arterial and venous blood, as well as a saaall capillary content, but the venous blood will heavily outweigh the arterial blood because the great majority (on the order of 70-80 percent) of the cerebral blood is in the venous compartment.
. It will be appreciated that the foregoing ..
relationship may be usefully implemented in computer software by appropriate algorithm, particularly in view of the comments and discussion set forth previously herein in conjunction with Figs. 1-6 inclusive. In this regard, hov~e~vsr, it is to be emphasized once again that the invention is preferably implemented by way of the preferred embodiments noted and the accompanying commen-tart'; in particular, the transmitted light of wavelengths w, w', etc. is preferably sequentially applied in short bursts (pulses) by use of a suitable number of repeti-tions which alternate application of the selected d'V~ 92.'2123 ~ ~ ~ ~ ~ ~ PCT/LJS92/04654 wavelengths. Detection of resulting light for each such burst thus occurs at both the near and far locations essentially simultaneously, and is preferably obtained on a.time-gated basis corresponding to the occurrence of the pulsed incident light wavelengths, praviding synchron~us detection/demodulation techniques. Of course, the - detected light burst intensities at the selected wavelengths constitute an analog quantity as detected, and these are preferably converted to digital form for subsequent processing. The computer 20 noted in connection with Figs. 1 and 2 is preferably utilized to control all time-based functions, as well as for the processing of digitized data in accordance with the aforementioned algorithm.
It should be expressly noted that differential processing (in essence, subtraction) of the near-far detection measurements is considered to be of the essence ins order to define the selected internal region which is to be examined, and in particular to exclude the effects of the sampled near field from the measurements of the desired far field, thereby eliminating not only boundary (initial impingement and peripheral penetration) effects but also those attributable to transmission through the skin, bone and dura by the selected examination spectra.
This processing may be carried out incrementally, prior to each iterative spectrophotometric transmission and detection sequence, since the digitized data may readily be stored on an increment-by-increment basis and used for further processing (or storage) as desired. It is believed useful, however, to accumulate an average for each particular type of measurement over a given number of cycles--(,i.e., bursts of investigative light at a common wavelength, received at a particular sensor), and then subtractively process the resulting averages in the manner just noted above.
It will be appreciated from the foregoing that the end result thus obtained will provide a quantified value for regional oxygen saturation of hemoglobin in the brain iV0 92/2123 FLT/US92/04654 7_ on an essentially instantaneous, real-time basis, which may be presented in various forms (e. g., as a numeric display on the computer monitor, updated at selected intervals or in accordance with other such garameters), or in a variety of other forms such as graphs, charts, etc. As an example of such formats, and to further illustrate the nature and value of information obtainable in accordance with the invention, reference is made to Figs. 7-1~, together with the following commentary pertaixiing thereto.
Fig. 7 presents a graphical-form chart showing measured regional cerebral hemoglobin saturation with respect to ti~ae,.obtained by actual clinical measurement of a human subject undergoing progressive cerebral hypoxia. As will be readily observed, a rapid shift from baseline to abnormal values (less than 55 percent) is clearly indicated, commencing at about the four minute point, as a result of the progressive hypoxia, as is the very rapid return to baseline (and in fact slightly elevated initial level exceeding baseline) following corrective patient respiration on one-hundred percent oxygen. Particular reference should be given to the arrow indicated on the abscissa scale, which indicates the point in time at which an analog EEG, retrospectively evaluated by a clinician on a "blind" basis, first indicated abnormal theta-delta activity. As may readily be seen from this, the Blear indications of serious abnormality provided in accordance with the invention occurred well over a full minute before the earliest such EEG indication, and of course this occurs through ongoing, real-tizae quantified measurement in terms of percent oscygenation, whereas the EEG chart is retrospec-tively studied.
Fig. 8 comprises a chart somewhat analogous to that presented in Fig. 7 and described above, but showing a longer-duration procedure during which the monitored patient underwent elective hypothermic cardiac standstill during surgical repair of a giant intracranial Pt_°T/~,JS92/04654 i~VO 92/2123 aneurysm. As will readily be noted, a clearly-perceptible decline from a baseline value in the range of 60-70 percent saturation commences at approximately 30 minutes, and extends to approximately 45 minutes, during which time the patient was completely off bypass and had no cerebral blood flow, and thus no oxygen delivery (under the aforementioned hypothermic conditions).
Following reperfusion at approximately the 45 minute point, brain oxygen saturation is shown to rapidly return toward baseline, and may clearly be monitored during the highly important ensuing period.
Fig. 9 comprises a different form of chart, -'-presenting '°optical density" (i.e., attenuative effect) at the reference wavelength over a period of time, in seconds, as evidenced by the detected light intensity information received separately at the near and far detector locations following introduction of a bolus of infrared tracer material. This chart thus shows transit of the tracer through the cerebral vasculature: that is, selective introduction of the tracer in the internal carotid artery results in initial presence thereof only in the deep tissue; thus, ipsilateral spectroscopic measurements made in accordance with the invention show (bottom trace) relatively immediate detection of the tracer at the "far" receiver monitoring the deeper brain tissue, without any attendant indication at the "near"
receiver (upper trace) which monitors superficial tissue, etc., until substantially later, after the tracer has recirculated through the heart and entered the external carotid system, at approximately fifty seconds after the initial introduction of the tracer. In this regard, it will be noted that the far receiver also shows recircula-tion of the bolus at this second point in time, as well as graphically displaying the declining persistence of the tracer within the deep tissue over this interval.
Fig. 10 constitutes a further graphical showing illustrative of the versatility, usefulness and value of information provided in accordance with the invention, by way of a pair of comparative traces showing (lower trace) continuous regional cerebral oxygen saturation (characterizing "deep", i.e., brain, tissue) as compared to that characterising only the superficial tissue, i.e., scalp and skull (upper trace), an actual trauma patient who suffered a serious closed-head injury and was continuously monitored. As may readily be observed by noting the change occurring at the vertical line disposed at a point representing approximately 27.25 hours after the onset of monitoring, progressive cerebral desaturation commences notwithstanding the fact that the superficial blood supply remains fully oxygenated. It is to be noted that the first clinical manifestation of--brain desaturation in this patient occurred more than two hours later, at approximately 29.5 hours.
From the foregoing, the significance and value of information provided in accordance with the invention is believed readily apparent, corroborating expectations based upon appreciation of the fact that cerebral venous oxygen saturation should constitute an excellent indicator of the adequacy of cerebral oxygen delivery and/or cerebral oxygen extraction, and thus of brain vitality as a general matter. That is, cerebral oxygen extraction causes rapid changes in cerebral venous oxygen saturation when cerebral oxygen delivery decreases for any reason, as for example the presence of systemic hypoxia, cerebral oligemia, systemic anemia, etc., even though cerebral oxygen consumption may remain normal. In this regard, the very advantageous results obtained through the spatial resolution techniques noted, providing for specific and independent monitoring of ingormatic~~~from deep vascular beds or tissue, provides gor desirable organ-specific or area-specific determina-tions made well below the skin. Further, although the specific accuracy and sensitivity of oximetry measurements in accordance with the invention in heterog~:neous tissue such as the scalp and adjacent or near underlying area remain to be seen, and potentially U
~Y~ 92121283 PCT/US92104fi54 further defined, the usefulness of the resulting informs--tion is clearly demonstrated by examples such as those presented in Figs. 9 and 10, as discussed above.
As for specific accuracy of regional oxygen saturation determinations pursuant to the mathematical paradigm set forth above, comparative evaluation may .readily be accomplished for any specific implementation, and has in fact been done by use of in vitro human blood which was suitably warmed and artificially oxygenated to various saturations, and then subjected to comparative testing with a standard lab cooximeter (using a custom-ized cuvette with immersible light guides for access by -apparatus in accordance with the invention). ~y utiliz-ing linear regression analysis, highly~significant correlation is shown which supports the underlying soundness of the mathematical approach discussed above.
Of course, appropriate scale factors may be determined in this general manner for any desired specific application of the methodology disclosed herein, and used to calibrate or correlate the actual output of the implemented apparatus, for example by conventional computer data-processing techniques such as embodying the seals factors in appropriate look-up tables, for example.
It may be noted that such procedures may also provide a desirable or useful calibration technique in any event.
It should be further pointed out that since the quantified values of regional hemoglobin oxygen saturation provided in accordance with the invention constitute field values, i.e., represent hemoglobin contained in three separate vascular compartments (arterial, venous and microcirculatory), these quantified values represent the weighted average of the three different vascular compartments. While hydraulic analysis of the cerebral vascular system, as evidenced by published information, supports a cerebral blood volume distribution that is in accordance with that set forth above, it~may be noted that the specific relative size of each such blood volume compartment is in fact dynamic in W~ 92/21283 PCT/US92/04654 a given patient depending upon the ratio of oxygen supply to and demand during conditions of physiologic stress, anatomic location, and in numerous other factors;
consequently, an ideal reference methodology would simultaneously measure the actual relative blood volume of these three different compartments, preferably on a regional basis. Nonetheless, employment of assigned weighting values in the mathematical paradigm used, pursuant to the published hydraulic or other analytic information available, is quite sufficient for purposes of providing useful clinical instrumentation. Of course, the presence of extravascular cerebral blood collection, for example in the subarachnoid, subdural, or intraparenchymal tissue compartments, could or may potentially interfere with the strict accuracy of the quantifications provided, even though relative or trend data based thereon would seemingly still be of considerable importance; further, the spatial resolution capabilities of the inve::~ion may in fact provide a way to comparatively assess such anomalies, particularly if they are reasonably well defined. At the same time, the paradigms set forth above, being primarily designed to measure and account for extraparenchymal conditions, have the potential to overcome such problems.
Accordingly, it is believed that a highly useful and novel methodology is provided by the invention, particularly, but certainly not exclusively, as applied in the preferred embodiment discussed herein above, as well as in other related or analogous applications. It is to be understood that the foregoing description of a preferred embodiment of the invention is provided for purposes.af~description and illustration, and not as a measure of the invention, whose scope is to be defined solely by reference to the ensuing claims. Thus, while those skilled in the art may devise embodiments of the particular concepts presented in the foregoing illustra-tive disclosure which differ somewhat from the particular embodiment shown and described in detail_herein, or may W~ 92/21283 PCT/US92/04654 make various changes in structural details to the illus-trated embodiment, all such alternative or modified embodiments which utilize the concepts of the invention and clearly incorporate the spirit thereof are to be considered as within the scope of the claims appended herebelow, unless such claims by their language specifi-cally state otherwise.
h
TECHNICAL FIELD
This invention relates generally to in vivo spectrophotometric methods and apparatus, for examining and/or monitoring biological tissue, substances and/or conditions in living subjects, in particular humans.
More particularly, the invention relates to the novel application of such in vivo methods and apparatus to provide a new form of biomedical device for non-invasively monitoring oxidative metabolism in mammalian (e.g. human) subjects on an in vivo basis, a specific and preferred embodiment of which comprises means for so-monitoring regional oxygen saturation in the brain, and for providing a quantitative readout thereof in terms familiar tee medical practitioners, i.e., percent oxygen saturation.
BACKGROUND
Bpectrophotometry has, of course, long been used as a valuable investigative tool in various scientific fields, particularly biological and medical research, and various applications of the underlying principles utilizing selected wavelengths of light in the near infrared range (often referred to as N.I.R.
spectrophotometry) have for quite some time been utilized for certain in vivo procedures and/or investigation on human beings. For example, a frequently-encountered such device is the pulse oximeter conventionally used in hospitals and other medical facilities to provide a direct indication of arterial oxygen saturation by means of a clip or the like which fastens to an appendage such as the ear or finger of the patient. As has been noted by a small but growing field of investigators, the potentialTy~useful applications of N.I.R. in vivo spectrophotometry are considerably broader and more diverse than this, however, due to the interesting and ' useful characteristic of ?t.I.R. wavelengths in being able to pass through ("transmiss") biological substance such as human skin, bone, and tissue for at least a length of several centimeters, and a useful: brief description and WAD 92/21283 ~ 11 p '~ ~ ~ PCT/US92104654 commentary as to this is set forth in patents attribut-able in at least part to the present inventor (see for example U.S. Patent No. 4,570,638j, as well as in the various references of record therein. In the latter regard, particular reference is made to the patents issued to Jobsis et al, e.g. U.S. Patents Nos. 4,281,645, .4,223,680 and 4,321,930.
While previous developments in the general field of N.I.R. in vivo spectrophotometry, as noted above, have no doubt provided interesting and at least potentially useful insights and information heretofore, many important,further developments and applications no doubt remain to be made, and certain of these are likely to be of considerable importance~to medical practitioners. For example, accurate, meaningful, non-intrusive monitoring of brain status and viability is a most important need which prior technology has not sufficiently satisfied.
As is well known and widely appreciated, the brain is a delicate and easily-damaged portion of human anatomy, while at the same time being the epicenter of neurological and physiological function. Brain damage through injury or cerebral vascular disease is responsi-ble for numerous deaths and serious illnesses each year, involving on the order of at least 100,000 surgical procedures annually in recent years. Brain vitality is primarily a function of oxidative metabolism, and the pres~ominant cause of neurological dysfunction and w malfunction relates to the lack of sufficient brain oxidation, typically as a result of obstruction or othex~rise insufficient arterial blood flow to the brain.
Of course, this can occur even during surgery, and it has been estimated that at least 2,000 patients die each year in the United States alone due to anesthetic accidents, while numerous other such incidents result in brain damage of some degree; at the same time, certain major and complex surgical procedures, particularly of a neurological, cardiac or vascular nature, may require induced low blood flow or pressure conditions, which W~ 92/2~2~3 ~ PCTlUS92/fl46S4 inevitably involves the potential of insufficient oxygen delivery to the brain. At the same time, the brain is the human organ which is most intolerant of oxygen deprivation, and brain cells will die within a few minutes if not sufficiently oxygenated. Moreover, such cells are not replaced, and thus involve irreversible -brain damage which may potentially result in paralysis, disability, or even death.
Accordingly, the availability of immediate and accurate information concerning the state of brain oxygen saturation is of critical importance to anesthesiologists and surgeons, as well:as other involved medical practi-a tioners, particularly since the patients involved are typically in an unconscious state and thus unable to-provide information by ordinary physical response. Up until the present time, however, the instrumentalities available for use, including such things as electroencephalograph ("EEG"), arterial pulse oximeter and blood pressure monitors, etc., and even invasive catheter monitoring of blood oxygen content, acidity, etc. by penetration of the jugular bulb (jugular vein) do not provide accurate, ongoing, timely (instantaneous) information as to cerebral (brain) blood oxygenation state, particularly since the brain blood supply is extensive, diffuse, pervasive, and largely venous in nature rather then arterial. Of course, it is also thus devoid of conventional pulsative characteristics essen-' tial to the operation of conventional oximeters.
Accordingly, such devices are not appropriate for cerebral usage, and of course they are typically made to be applied only to peripheral tissue or appendages in any event, i.e...~ a finger or an ear lobe, and are not utilized in conjunction with venous blood. Of course, jugular bulb catheters are highly invasive and relatively traumatic: at the same time, they merely provide blood samples which are removed and analyzed in another location, at a subser~uent point in time, and thus only WO 92/2123 ~ ~~ ~ PCT/US92/04~54 address the state of venous blood after it has left the brain.
BRIEF SUM~~ARY OF INVENTION
In a specific and particular sense, the present invention provides a spectrophotometric cerebral oximeter, which non-invasively and harmlessly provides -accurate and continuous real-time information as to the oxygenation state of the human brain, on an in vivo basis, without attendant patient stress or discomfort of any nature. More broadly considered, the present invention provides in vivo spectrophotometric methods and apparatus adaptable to other relatively analogous biomedical procedures and functions, for monitoring oxidative metabolism and/or other physiologic function, condition, or state.
In the particular preferred embodiment disclosed, the invention provides an in vivo, spectrophotometric cerebral oximeter which will non-invasively provide continuous monitoring of cerebral oxidation, and will do so in a form and format of a nature immediately under-standable and familiar to physicians, i.e., percent oxygen saturation. Further, the cerebral oximeter so provided operates by examining (sampling) the cerebral blood supply throughout the complete vascularization (arterial, venous, and capillary systems) within the area of investigation, and the particular region investigated is or may be selectively accessed in accordance with the invention, i.e., the tissue volume examined is regional in nature and of a generally predetermined extent and location, constituting less than the entire brain or other area. Still further, the apparatus and methodology in accordan,~e with the invention includes the provision of a convenient and readily-usable sensor which may for example be used in a number of different locations, and/or moved from one location to another, for compara-tive consideration of the regions selectively accessed and examined, whether cranial or otherwise.
VV~ 92/21283 PCi'/U~92/t~46S4 _5_ Accordingly, the cerebral oximeter in accordance with the invention examines, and measures, blood oxygen saturation (and thus, oxidative metabolism) in the entire array of blood vessels present in the cranial region being monitored, which in the brain may generally be considered as comprising (by volume) approximately 75 -percent venous, 20 percent arterial, and 5 percent capillary. Thus, the cerebral oximeter provided in accordance with the invention addresses not only oxygen delivery via hemoglobin molecules moved arterially, but in addition addresses the general, overall state of cerebral oxygen consumption, which is of course directly ralated to brain vitality and state, and indicative of continued viability. As already indieated, the invention provides such information on an instantaneous real-time basis, and as a result provides critical immediate information capable of clearly and quantitatively indicating the need for urgent measures to provide increased or decreased cerebral oxygen supply or consumption (metabolic activity), momentary responses to which may well prevent serious neurologit~al or other trauma or injury.
In addition, the cerebral oximeter or other such apparatus provided in accordance with the invention is convenient to use, non-invasive and non-traumatic, produces no attendant side effects, and provides specific, quantified information of a type not previously available. At the same time, such apparatus is compact and relatively portable in nature, may provide direct visible monitoring vii CRT or other visual display, and provides digitally storable data which may readily be maintainec't~,~or future review or comparison or printed out in hard copy, plotted, etc., and/or periodically accessed to provide ongoing trend data, for displaying or analyzing changes which occur over selected periods of time. As such, the apparatus may be used in such diverse circumstances as emergency or trauma conditio::.~, whether in the field (at the scene of accidents, etc. ,nor WO 9212~2~3 Pf.'T/US92/~654 example) or in emergency medical centers, intensive care units, surgical operating rooms, hospital trauma centers, or at bedside, etc. In particular, however, use during ongoing surgical procedures is clearly anticipated as satisfying an existing and important medical need, particularly during such procedures as brain surgery, . open heart, organ or other transplant surgery, or that involving major blood vessels, for example, carotid endarterectomy; or other bypass surgery, etc., where blood flow is maintained through heart-lung machines and there is no arterial pulse present at all in the braiw or body.. a ..:. : ::. ::
The".foregoing major objectives;'advantages and considerations of the invention, together with and including others, will become more apparent following consideration of the ensuing specification, particularly taken in conjunction with the appended drawings, briefly described hereinafter. Once again it is pointed out that the apparatus and methodology principally described hereinafter constitutes merely a preferred embodiment of the underlying invention, and does not specifically address other and further aspects thereof which will or may become further appreciated by those skilled in the art after consideration of the overall disclosure herein.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a pictorial schematic representation simplistically showing the basic application and utiliza-tion of apparatus in accordance with the invention:
Fig. 2 is a further pictorial schematic representa-tion somewhat similar to Fig. 1 showing additional aspects of the subject matter disclosed;
Fig.. 3;'is an end view of a first optical sensor assembly for use in conjunction with the invention;
Fig. 4 is a pictorial side view representation of a different form of optical sensor, of a more preferred nature;
2~~~'~ 1~J
WO 92/2I2~3 PCT/US92/0465~
Fig. 5 is a schematic representation depicting the regional examination of the head and brain in accordance with the invention:
Fig. 6 is a graphical representation illustrating the spectral absorption characteristics of hemoglobin;
Fig. 7 is a graphical representation showing _ measured cerebral hemoglobin oxygen saturation in accordance with the invention in a first test subject;
Fig. 8 is a graphical representation showing measured cerebral hemoglobin oxygen saturation in accordance with the invention in a second test subject;
Fig. 9 is a graphical representation showing cerebral vaseular oxygenation activity contrasted with extracerebral oxygenation~of the scalp and skull, as measured by the near and far detectors provided in the sensor assembly utilized by the invention: and Fig. 10 is a further graphical representation showing cerebral oximetry measurements in accordance with the invention.
DESCRIPTION OF PREFERRED EMBODIMENTS
Oxygen is supplied to the brain by hemoglobin molecules contained-in the blood supply, to which the oxygen molecules become bonded during the oxygenation process which occurs in the lungs as the blood is pumped by the heart through arteries and capillaries to the brain. As previously stated, the brain extracts oxygen from the hemoglobin by oxidative metabolism, and resulting carbon dioxide molecules are carried away through the capillaries and veins to the lungs for reoxygenation. Generally speaking, the optical spectrophotometry utilized by the invention is based upon the seler~tive attenuation of particular light spectra in the near infrared range which is exhibited by oxygenated hemoglobin as compared to reduced (deoxygenated) hemoglobin contained in the blood present within the cerebral region under examination. Figs. 1 and 2 pictorially and schematically show the overall or general application.of the apparatus and methodology of the invention to the human cerebrum. Thus, Figs. 1 and 2 show a human subject 10 upon whom apparatus in accordance with the invention is being utilized, such apparatus comprising a sensor means 12 for applying and receiving selected light spectra to a particular region 14 of the brain through or via conductors 16 (which, as subsequently noted, may be electrical or optical in nature), from or in conjunction with an infrared spectrophotometry unit 18 which includes in part a small digital computer 20 having a monitor 22 on which various forms of readout information may be presented. As generally shown in a pictorial and schematic manner by Fig. 2, the sensor. assembly 12 applies selected light wavelengths which may emanate from a broadband source 24 (e. g., an incandescent lamp) and be selectively determined by narrow-bandwidth (monochromatico) filters 26, although as subsequently noted a preferred embodiment utilizes dedicated light-emitting diodes ("L.E.D.s") which produce the selected light spectra, and the computer 20 generally includes an A/D converter section 28, control circuitry 30 (depicted as a circuit board configured to mount in the expansion slats of computer 20), together with requisite computer memory 32 and an operator control in the form of a keyboard 34.
The sensor assembly 12 may as a general matter be in accordance with one embodiment that is shown for example in Fig. 3. It may be noted that, as shown in Fig. 3, such a sensor assembly 12' generally comprises a housing or other support 36 which carries a light-emitting element 38, a first light-detector or receiver 40 (i.e., the " near " receiver) and a second such detector or receiver 42 (the "far " receiver) which is disposed a predetermined and particular distance away from the source 38 and the " near " receiver 40. In the ,ii -g-sensor assembly 12" is more elongated in overall shape and preferably has a somewhat flexible support 136 which carries the light source 138 and the near and far receivers 140, 142, respectively, all arranged in a longitudinal array, disposed along a common linear axis.
It may be noted that in this preferred form the source 138 comprises a pair of separate (but commonly-mounted} light-emitted diodes which provide at least two particularly-selected wavelengths (described in more detail subsequently herein), and the receivers 140 and 142 comprise photodivdes. As a result, the entire sensor assembly 12" is relatively small and compact, lightweight, and thin, as well as being at least modestly flexible; of course in this form the conductor array 16' comprises electrical conductors, since the operative elements are electro-optical emitters and detectors. Of course, such components operate with very low levels of , electrical excitation, and the actual conductors 16' are each insulated from one another and carried within an insulating outer sheath 116.
Regardless of the particular form of sensor assembly 12 which is utilized, the inclusion and relative spacing of the source 38, 138, near receiver 40, 140, and far receiver 42, 142 are of importance to the proper function and performance of apparatus. in accordance with the invention.
In general, however, the near receiver (40, 140) is close to but spaced a particular distance from the source (38, 138) so that the photons (light energy) which it detects in ,: , , 11 ~ '~ .1 f;
WO 92!21283 PCTIL'S92/046~4 response to the emission of selected light spectra by the source will traverse primarily only the skin (scalp) and bone ( skul l ) of the subj ect 10 , whereas the °' far"
receiver (42, 142) is disposed a particular further distance from the source whereby the light energy (photons) which it receives samples a deeper tissue volume comprising primarily brain tissue. This selected brain tissue volume which is sampled, as generally delineated by the curving line designated 114 which illustratively depicts the mean optical path of the photons received at the far receiver 42, 142, constitutes the selected region 14 noted previously (Fig:el), and it will be~observed that such region constitutes a particu~
lar internal volume within the overalllbrain content whose location is determined by the relative disposition and separation of the source 38, 138, near receiver 40, 140, and far receiver 42, 142, together with the relative placement and location of the sensor assembly 12 upon the head of the subject 10.
Of course, there are practical limits to the maximum distance at which the far receiver (40, 140) may be disposed relative to the source (38, 138), since the level of light energy used must be less than that which would be harmful, while at the same time there must be more than merely trivial amounts of light energy received at the far receiver, in order to obtain meaningful data from the spectral modulation or attenuation of the light by the substance transmissed. As presently envisioned, it is probably not effective or useful to dispose the far receiver directly opposite (across the entire skull width) from the source, by which the complete width or diameter o-f,'the brain is transmissed, and it will be noted that in the configurations discussed above and depicted in the drawings, both the near and far receivers operate more in a "reflectance" mode than a "transmission" mode as those terms are conventionally used (i.e., they are disposed along mean optical paths 'which are curved, and_are relatively close to the i source). Of course, as already indicated, this is directly consistent with monitoring regional brain function, which represents the preferred embodiment of the invention. By way of example, in a particular such preferred embodiment the distance between the source and near receiver is approximately 0.3 inches, while the distance between the source and far receiver is approxi-mately 1,0 inches.
Generally speaking, some of the basic principles underlying the invention may be appreciated by reference to Fig. 6, which shows the known absorbtivity of hemoglobin to selected N.I.R. light wavelengths. As there illustrated, the spectral absorption characteris-tics of oxygenated hemoglobin describe a family of curves which intersect, and reverse, at a wavelength of approxi-mately 800 nanometers ("nm"), which constitutes the isobestic point (typically considered to be at 815 nm).
As illustrated, the absorbtivity of reduced (deoxygenated) hemoglobin rises progressively at lower wavelengths as a function of the relative absence of oxygen, the highest such curve thus rep resenting fully deoxygenated hemoglobin and the lowermost such curve representing fully oxygen-saturated hemoglobin. As shown, these curves describe a peak in the general range of about 760 nm, as well as a valley or dip at approxi-mately 730-740 nm. Accordingly, as is already known, by monitoring the optical response at selected wavelengths, i.e., by comparing intensity of light received at wavelengths less than the isobestic point with that received at the latter, and making appropriate computa-tions, the oxygen content of sampled hemoglobin may be determined. In accordance with the invention, such sampling is preferably carried out at wavelengths representing points of most gradual change, rather than WO 32!21283 ~ ''~ ~ ~ PCTlUS92l04654 points representing steepest slopes: accordingly, a first sampling wavelength may be in the range of about 735 nm, and another may be at approximately 760 nm. Since the specific point at which isobestic conditions exist may vary somewhat as a result of a number of factors, the reference wavelength is preferably selected to be at approximately 805 nm.
In view of the foregoing, it will be appreciated that the primary focus of this description of preferred embodiments is based upon N.I.R. spectrophotometric procedures directed toward measurement: of oxyhemoglobin and deoxyhemoglobin, in order to provide a cerebral .:
oximeter as..noted,:above, i.e., an apparatus for providing quantified information as to regional oxygen saturation in the composite vasculature of the brain, and the following further description sets forth mathematical descriptions and characterizations of the underlying rationale and procedure for such a device. It should be expressly noted, however, that the underlying invention is not necessarily limited to this specific application, and indeed is believed to have direct or meaningful application to other in vivo procedures which are or may be primarily attributed to or defined in meaningful part by other well-characterized chromophores, particularly (but not necessarily) in other somewhat analogous regional areas or domains, where information relative to biological processes in such a reasonably defined and distinctive area is important, and it is necessary or useful that such information be free of distortions attributable to hemoglobin or other attributes character-izing the satin, bone, and dura which is superficial to the more deeply-located region to be investigated.
With further and continuing reference to the particular preferred embodiment under discussion, it will be appreciated that the methodology of the invention utilizes diffused near-infrared spectroscopic procedures of a generally transmission-mode character for quantita-tive evaluation of tissue which is highly scattering and i~~ 92/21283 ' ~ ~ 6 PCT/US92/0~651t partially absorptive in nature, utilizing spatial resolution for region definition. Since wavelength-specific attenuation of light propagated through such tissue is a function of the chromophores, their extinction coefficients, their concentrations, and the distance photons travel in the tissue, the basic relationship may be analogized too, and expressed in accordance with, the Beer-Lambert relationship as set forth below, even though this is in fact deemed specifi-cally descriptive of homogeneous non-scattering media:
Itw> '~ It~~e In the foregoing expression, the quantity I(w) represents intensity of transmitted light at wavelength w, the term I(w)0 represents the intensity of the inci-dent light at wavelength w, the term a represents the molar extinction coefficient of the light-absorbing mol~cul~ (chromophore), the term C represents the content of such chromophore in the tissue under examination, and the term s represents the photon pathlength in the tissue of interest. By use of this relationship, a fundamental approximation is obtained for interpreting the N.I.R.
spectra utilized; since there are at Least three signifi-cant chromophores present in brain tissue, each with separate extinction coefficients and concentrations, the above-noted relationship may be modified and expressed as follows:
N
~~~ yw~iwb ~ ~ aiw, ~l~ys The measurements made at the selected examination wavelengths may be usefully referenced by subtracting them from referenced measurements made at second selected wavelength i.e., the isobestic point of hemoglobin noted above in connection with Fig. 6. Since the above relationship refers to absorption at wavelength w, absorption at a s~cond wavelength w' is subtracted from WO 92/2123 ~ ~ ~ ~ l ~ ~j PCT/U~~2/04g54 °14°
that at the first wavelength, w, yielding the following expressions ~ ~g~rzw~~r ~ ~c~~. 3'~ ~ ~~'. jl~'(i)~
~1 The foregoing expression may be simplified by use of arbitrary definitions; 1.e., everything directly measured may be defined by the variable M. Since the difference in extinction coefficient is also a known, it may be defined by the tens d. Accordingly:
c,~> ~ ° c~;~c~~ + 1~ I~~t~cW~~
c~. ;~ ' ~c.~, ;) ~ ~c~~. ;~
Thus, the expression describing absorption at a second wavelength w' subtracted from that at a first wavelength w may be reduced to the following simpler notation:
~ ~ dc.., ,7Cci~s s Consideration of the simplified relationship dust express~d reveals that the variable of interest, ~chromophore concentration, may be quantified for oxyh~raoglobin and deoxyhemoglobin if such expression is solved by making (N+1) measurements of M to solve for C(p)s (oxyhemogolbin) and C(p)s (deoxyhemogolbin) independently. These values are proportional to chromophore content. The value s is a constant, and by i~~ 92/212$3 2 ~ ~ PCT/1J~92/04fi54 calculating the ratio of deoxy- to oxy- hemoglobin, this constant cancels out of the expression. If this is assumed to be constant, the number of unknowns does not increase subsequent measurements, and this assumption appears to be well-supported. Thus:
C~.r~~~ _ ~c~.~Cc~ ~ I-i~
In the foregoing expression, the variable fir represents the hemoglobin ratio of deoxy- to oxyhemoglobin, which raay then be used to solve for the r~gional saturati~n of hemoglobin designated rSHgbo2 below:
1!( 1 + ) _ ~( ~. s) ~ r~I~ ' B
It will therefore be se~n that the term "rSFigboa", defined as "regional saturation of hemoglobin", constitutes the ratio of oxygenated hemoglobin to total hemoglobin in the sampled field (defined region) of the brain under investigation. As previously stated, this region will contain both arterial and venous blood, as well as a saaall capillary content, but the venous blood will heavily outweigh the arterial blood because the great majority (on the order of 70-80 percent) of the cerebral blood is in the venous compartment.
. It will be appreciated that the foregoing ..
relationship may be usefully implemented in computer software by appropriate algorithm, particularly in view of the comments and discussion set forth previously herein in conjunction with Figs. 1-6 inclusive. In this regard, hov~e~vsr, it is to be emphasized once again that the invention is preferably implemented by way of the preferred embodiments noted and the accompanying commen-tart'; in particular, the transmitted light of wavelengths w, w', etc. is preferably sequentially applied in short bursts (pulses) by use of a suitable number of repeti-tions which alternate application of the selected d'V~ 92.'2123 ~ ~ ~ ~ ~ ~ PCT/LJS92/04654 wavelengths. Detection of resulting light for each such burst thus occurs at both the near and far locations essentially simultaneously, and is preferably obtained on a.time-gated basis corresponding to the occurrence of the pulsed incident light wavelengths, praviding synchron~us detection/demodulation techniques. Of course, the - detected light burst intensities at the selected wavelengths constitute an analog quantity as detected, and these are preferably converted to digital form for subsequent processing. The computer 20 noted in connection with Figs. 1 and 2 is preferably utilized to control all time-based functions, as well as for the processing of digitized data in accordance with the aforementioned algorithm.
It should be expressly noted that differential processing (in essence, subtraction) of the near-far detection measurements is considered to be of the essence ins order to define the selected internal region which is to be examined, and in particular to exclude the effects of the sampled near field from the measurements of the desired far field, thereby eliminating not only boundary (initial impingement and peripheral penetration) effects but also those attributable to transmission through the skin, bone and dura by the selected examination spectra.
This processing may be carried out incrementally, prior to each iterative spectrophotometric transmission and detection sequence, since the digitized data may readily be stored on an increment-by-increment basis and used for further processing (or storage) as desired. It is believed useful, however, to accumulate an average for each particular type of measurement over a given number of cycles--(,i.e., bursts of investigative light at a common wavelength, received at a particular sensor), and then subtractively process the resulting averages in the manner just noted above.
It will be appreciated from the foregoing that the end result thus obtained will provide a quantified value for regional oxygen saturation of hemoglobin in the brain iV0 92/2123 FLT/US92/04654 7_ on an essentially instantaneous, real-time basis, which may be presented in various forms (e. g., as a numeric display on the computer monitor, updated at selected intervals or in accordance with other such garameters), or in a variety of other forms such as graphs, charts, etc. As an example of such formats, and to further illustrate the nature and value of information obtainable in accordance with the invention, reference is made to Figs. 7-1~, together with the following commentary pertaixiing thereto.
Fig. 7 presents a graphical-form chart showing measured regional cerebral hemoglobin saturation with respect to ti~ae,.obtained by actual clinical measurement of a human subject undergoing progressive cerebral hypoxia. As will be readily observed, a rapid shift from baseline to abnormal values (less than 55 percent) is clearly indicated, commencing at about the four minute point, as a result of the progressive hypoxia, as is the very rapid return to baseline (and in fact slightly elevated initial level exceeding baseline) following corrective patient respiration on one-hundred percent oxygen. Particular reference should be given to the arrow indicated on the abscissa scale, which indicates the point in time at which an analog EEG, retrospectively evaluated by a clinician on a "blind" basis, first indicated abnormal theta-delta activity. As may readily be seen from this, the Blear indications of serious abnormality provided in accordance with the invention occurred well over a full minute before the earliest such EEG indication, and of course this occurs through ongoing, real-tizae quantified measurement in terms of percent oscygenation, whereas the EEG chart is retrospec-tively studied.
Fig. 8 comprises a chart somewhat analogous to that presented in Fig. 7 and described above, but showing a longer-duration procedure during which the monitored patient underwent elective hypothermic cardiac standstill during surgical repair of a giant intracranial Pt_°T/~,JS92/04654 i~VO 92/2123 aneurysm. As will readily be noted, a clearly-perceptible decline from a baseline value in the range of 60-70 percent saturation commences at approximately 30 minutes, and extends to approximately 45 minutes, during which time the patient was completely off bypass and had no cerebral blood flow, and thus no oxygen delivery (under the aforementioned hypothermic conditions).
Following reperfusion at approximately the 45 minute point, brain oxygen saturation is shown to rapidly return toward baseline, and may clearly be monitored during the highly important ensuing period.
Fig. 9 comprises a different form of chart, -'-presenting '°optical density" (i.e., attenuative effect) at the reference wavelength over a period of time, in seconds, as evidenced by the detected light intensity information received separately at the near and far detector locations following introduction of a bolus of infrared tracer material. This chart thus shows transit of the tracer through the cerebral vasculature: that is, selective introduction of the tracer in the internal carotid artery results in initial presence thereof only in the deep tissue; thus, ipsilateral spectroscopic measurements made in accordance with the invention show (bottom trace) relatively immediate detection of the tracer at the "far" receiver monitoring the deeper brain tissue, without any attendant indication at the "near"
receiver (upper trace) which monitors superficial tissue, etc., until substantially later, after the tracer has recirculated through the heart and entered the external carotid system, at approximately fifty seconds after the initial introduction of the tracer. In this regard, it will be noted that the far receiver also shows recircula-tion of the bolus at this second point in time, as well as graphically displaying the declining persistence of the tracer within the deep tissue over this interval.
Fig. 10 constitutes a further graphical showing illustrative of the versatility, usefulness and value of information provided in accordance with the invention, by way of a pair of comparative traces showing (lower trace) continuous regional cerebral oxygen saturation (characterizing "deep", i.e., brain, tissue) as compared to that characterising only the superficial tissue, i.e., scalp and skull (upper trace), an actual trauma patient who suffered a serious closed-head injury and was continuously monitored. As may readily be observed by noting the change occurring at the vertical line disposed at a point representing approximately 27.25 hours after the onset of monitoring, progressive cerebral desaturation commences notwithstanding the fact that the superficial blood supply remains fully oxygenated. It is to be noted that the first clinical manifestation of--brain desaturation in this patient occurred more than two hours later, at approximately 29.5 hours.
From the foregoing, the significance and value of information provided in accordance with the invention is believed readily apparent, corroborating expectations based upon appreciation of the fact that cerebral venous oxygen saturation should constitute an excellent indicator of the adequacy of cerebral oxygen delivery and/or cerebral oxygen extraction, and thus of brain vitality as a general matter. That is, cerebral oxygen extraction causes rapid changes in cerebral venous oxygen saturation when cerebral oxygen delivery decreases for any reason, as for example the presence of systemic hypoxia, cerebral oligemia, systemic anemia, etc., even though cerebral oxygen consumption may remain normal. In this regard, the very advantageous results obtained through the spatial resolution techniques noted, providing for specific and independent monitoring of ingormatic~~~from deep vascular beds or tissue, provides gor desirable organ-specific or area-specific determina-tions made well below the skin. Further, although the specific accuracy and sensitivity of oximetry measurements in accordance with the invention in heterog~:neous tissue such as the scalp and adjacent or near underlying area remain to be seen, and potentially U
~Y~ 92121283 PCT/US92104fi54 further defined, the usefulness of the resulting informs--tion is clearly demonstrated by examples such as those presented in Figs. 9 and 10, as discussed above.
As for specific accuracy of regional oxygen saturation determinations pursuant to the mathematical paradigm set forth above, comparative evaluation may .readily be accomplished for any specific implementation, and has in fact been done by use of in vitro human blood which was suitably warmed and artificially oxygenated to various saturations, and then subjected to comparative testing with a standard lab cooximeter (using a custom-ized cuvette with immersible light guides for access by -apparatus in accordance with the invention). ~y utiliz-ing linear regression analysis, highly~significant correlation is shown which supports the underlying soundness of the mathematical approach discussed above.
Of course, appropriate scale factors may be determined in this general manner for any desired specific application of the methodology disclosed herein, and used to calibrate or correlate the actual output of the implemented apparatus, for example by conventional computer data-processing techniques such as embodying the seals factors in appropriate look-up tables, for example.
It may be noted that such procedures may also provide a desirable or useful calibration technique in any event.
It should be further pointed out that since the quantified values of regional hemoglobin oxygen saturation provided in accordance with the invention constitute field values, i.e., represent hemoglobin contained in three separate vascular compartments (arterial, venous and microcirculatory), these quantified values represent the weighted average of the three different vascular compartments. While hydraulic analysis of the cerebral vascular system, as evidenced by published information, supports a cerebral blood volume distribution that is in accordance with that set forth above, it~may be noted that the specific relative size of each such blood volume compartment is in fact dynamic in W~ 92/21283 PCT/US92/04654 a given patient depending upon the ratio of oxygen supply to and demand during conditions of physiologic stress, anatomic location, and in numerous other factors;
consequently, an ideal reference methodology would simultaneously measure the actual relative blood volume of these three different compartments, preferably on a regional basis. Nonetheless, employment of assigned weighting values in the mathematical paradigm used, pursuant to the published hydraulic or other analytic information available, is quite sufficient for purposes of providing useful clinical instrumentation. Of course, the presence of extravascular cerebral blood collection, for example in the subarachnoid, subdural, or intraparenchymal tissue compartments, could or may potentially interfere with the strict accuracy of the quantifications provided, even though relative or trend data based thereon would seemingly still be of considerable importance; further, the spatial resolution capabilities of the inve::~ion may in fact provide a way to comparatively assess such anomalies, particularly if they are reasonably well defined. At the same time, the paradigms set forth above, being primarily designed to measure and account for extraparenchymal conditions, have the potential to overcome such problems.
Accordingly, it is believed that a highly useful and novel methodology is provided by the invention, particularly, but certainly not exclusively, as applied in the preferred embodiment discussed herein above, as well as in other related or analogous applications. It is to be understood that the foregoing description of a preferred embodiment of the invention is provided for purposes.af~description and illustration, and not as a measure of the invention, whose scope is to be defined solely by reference to the ensuing claims. Thus, while those skilled in the art may devise embodiments of the particular concepts presented in the foregoing illustra-tive disclosure which differ somewhat from the particular embodiment shown and described in detail_herein, or may W~ 92/21283 PCT/US92/04654 make various changes in structural details to the illus-trated embodiment, all such alternative or modified embodiments which utilize the concepts of the invention and clearly incorporate the spirit thereof are to be considered as within the scope of the claims appended herebelow, unless such claims by their language specifi-cally state otherwise.
h
Claims (19)
1. A spectrophotometric cerebral instrument suitable for conducting in vivo clinical examinations, comprising in combination:
means for applying selected spectra in the near infrared range to the head of a patient at a first location so that they transmiss at least selected portions of the brain after entry through the scalp and skull, said spectra including at least one reference wavelength and at least one investigative wavelength;
means for receiving light energy resulting from said applied spectra at second and third selected locations on the outside of said skull after said applied spectra have passed through said selected brain portions, said second and third locations being spaced from said first location by different distances;
means for producing corresponding and representative signals from the light energy received at said second and third locations;
and means for processing said signals by contrasting certain of said signals representative of light energy corresponding to said reference wavelength and received at said second location with signals representative of light energy corresponding to said investigative wavelength received at said second location to obtain a first resultant signal, contrasting certain of said signals representative of light energy corresponding to said reference wavelength received at said third location with signals representative of light energy corresponding to said investigative wavelength received at said third location to obtain a second resultant signal, and then contrasting said first and second resultant signals, to produce an output which is directly indicative of a predetermined regional cerebral pathology condition in said portion of said brain.
means for applying selected spectra in the near infrared range to the head of a patient at a first location so that they transmiss at least selected portions of the brain after entry through the scalp and skull, said spectra including at least one reference wavelength and at least one investigative wavelength;
means for receiving light energy resulting from said applied spectra at second and third selected locations on the outside of said skull after said applied spectra have passed through said selected brain portions, said second and third locations being spaced from said first location by different distances;
means for producing corresponding and representative signals from the light energy received at said second and third locations;
and means for processing said signals by contrasting certain of said signals representative of light energy corresponding to said reference wavelength and received at said second location with signals representative of light energy corresponding to said investigative wavelength received at said second location to obtain a first resultant signal, contrasting certain of said signals representative of light energy corresponding to said reference wavelength received at said third location with signals representative of light energy corresponding to said investigative wavelength received at said third location to obtain a second resultant signal, and then contrasting said first and second resultant signals, to produce an output which is directly indicative of a predetermined regional cerebral pathology condition in said portion of said brain.
2. A spectrophotometric instrument according to claim 1, including means for producing a visual readout from said output which is indicative of cerebral blood oxygenation.
3. A spectrophotometric instrument according to claim 2, wherein said readout is in terms of hemoglobin oxygen saturation.
4. A spectrophotometric instrument according to claim 2, wherein said means for processing said signals operates to contrast certain of such signals by subtracting certain of said logarithm equivalents from one another.
5. A spectrophotometric instrument according to claim 1, including means for processing said signals by producing logarithm equivalents of the signals received at said second and third locations prior to said contrasting of signals.
6. A spectrophotometric instrument according to claim 1, wherein said means for applying, receiving and processing function cooperatively such that said readout characterizes the blood oxygen content of a selected region of said brain.
7. A spectrophotometric instrument according to claim 6, wherein said output comprises a calculated composite indicator representative of the oxygen content of each of the different types of blood within said region.
8. A method of determining cerebral blood oxygenation by in vivo optical spectrophotometry comprising the steps of:
applying selected light spectra in the near infrared range to the head of a patient at a first location so as to transmiss portions of the brain through the scalp and skull;
receiving light energy resulting from and corresponding to said applied spectra at second and third selected locations on the outside of said skull, each spaced from one another and from said first location; producing corresponding signals representative of the light received at both said second and third locations; and processing said signals to produce therefrom a readout which is indicative of cerebral blood oxygen saturation in at least portions of said brain transmissed by said light spectra; said processing including the steps of contrasting certain of said signals representative of light energy corresponding to a selected wavelength received at said second location with signals representative of light energy corresponding to another selected wavelength received at said third location to obtain a first resultant signal having a value which is proportional to the ratio of deoxygenated hemoglobin with respect to oxygenated hemoglobin in at least said portions of said brain, and then using the value of said resultant signal to compute a further resultant signal having a value which is proportional to the ratio of oxygenated hemoglobin with respect to the sum of oxygenated hemoglobin and deoxygenated hemoglobin, said further resultant signal being indicative of cerebral blood oxygen saturation in said at least portions of said brain transmissed by said light spectra.
applying selected light spectra in the near infrared range to the head of a patient at a first location so as to transmiss portions of the brain through the scalp and skull;
receiving light energy resulting from and corresponding to said applied spectra at second and third selected locations on the outside of said skull, each spaced from one another and from said first location; producing corresponding signals representative of the light received at both said second and third locations; and processing said signals to produce therefrom a readout which is indicative of cerebral blood oxygen saturation in at least portions of said brain transmissed by said light spectra; said processing including the steps of contrasting certain of said signals representative of light energy corresponding to a selected wavelength received at said second location with signals representative of light energy corresponding to another selected wavelength received at said third location to obtain a first resultant signal having a value which is proportional to the ratio of deoxygenated hemoglobin with respect to oxygenated hemoglobin in at least said portions of said brain, and then using the value of said resultant signal to compute a further resultant signal having a value which is proportional to the ratio of oxygenated hemoglobin with respect to the sum of oxygenated hemoglobin and deoxygenated hemoglobin, said further resultant signal being indicative of cerebral blood oxygen saturation in said at least portions of said brain transmissed by said light spectra.
9. The method according to claim 8, wherein said signal-processing step is carried out by producing logarithmic equivalents of said signals representative of light received at said second and third locations prior to performing at least some of said signal-contrasting steps, whereby said contrasting steps are carried out by using said logarithmic equivalents.
10. The method according to claim 9, wherein at least some of said signal-contrasting steps in said signal-processing comprise subtracting certain of said logarithmic equivalents from one another.
11. The method according to claim 8, including the steps of selecting said first location as one where the scalp and skull overlie a plurality of said differently oxygenated types of blood, applying said selected spectra to transmiss each of said blood types, and processing said signals produce a readout which characterizes a selected composite of said differently oxygenated types of blood.
12. The method according to claim 8, including the step of processing said signals to produce a readout which characterizes a defined region of said brain.
13. The method according to claim 8, including the step of producing said readout as a visible display.
14. The method according to claim 13, including the step of producing said readout as a numeric display.
15. The method according to claim 13, including the step of producing said readout as a graph-form display.
16. The method according to claim 15, wherein one axis of said graph-form display is a time representation, whereby said display shows trend data.
17. The method according to claim 8, including the step of producing said readout in terms of cerebral blood oxygen saturation.
18. The method according to claim 17, including the step of producing said readout in terms of percent hemoglobin oxygen saturation.
19. A method of determining cerebral blood oxygenation by in vivo optical spectrotometry comprising the steps of:
applying selected light spectra in the near infrared range to the head of a patient so as to transmiss portions of the brain through the scalp and skull and to transmiss the overall vasculature present within said brain portions, including each of the various types of blood supply present within at least said brain portions, whether arterial, venous or capillary in nature; receiving light energy resulting from and corresponding to said applied spectra at selected locations on the outside of said skull, and producing corresponding and representative signals therefrom; and processing said signals in a manner to produce a readout which is indicative of the oxygen content of a composite of the total blood supply in said overall vasculature by calculating an average representative of the oxygen content present in all of said types of blood supply present within said brain portions and calculating a weighted average based upon said representative average and upon an assumed relative blood volume present for each of said different types of blood supply present within said brain portions.
applying selected light spectra in the near infrared range to the head of a patient so as to transmiss portions of the brain through the scalp and skull and to transmiss the overall vasculature present within said brain portions, including each of the various types of blood supply present within at least said brain portions, whether arterial, venous or capillary in nature; receiving light energy resulting from and corresponding to said applied spectra at selected locations on the outside of said skull, and producing corresponding and representative signals therefrom; and processing said signals in a manner to produce a readout which is indicative of the oxygen content of a composite of the total blood supply in said overall vasculature by calculating an average representative of the oxygen content present in all of said types of blood supply present within said brain portions and calculating a weighted average based upon said representative average and upon an assumed relative blood volume present for each of said different types of blood supply present within said brain portions.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71114791A | 1991-06-06 | 1991-06-06 | |
US711,147 | 1991-06-06 | ||
PCT/US1992/004654 WO1992021283A1 (en) | 1991-06-06 | 1992-06-04 | Optical cerebral oximeter |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2110716A1 CA2110716A1 (en) | 1992-12-10 |
CA2110716C true CA2110716C (en) | 2003-10-28 |
Family
ID=24856954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002110716A Expired - Lifetime CA2110716C (en) | 1991-06-06 | 1992-06-04 | Optical cerebral oximeter |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0597875A4 (en) |
JP (1) | JPH07500259A (en) |
CA (1) | CA2110716C (en) |
WO (1) | WO1992021283A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3433498B2 (en) * | 1993-06-02 | 2003-08-04 | 浜松ホトニクス株式会社 | Method and apparatus for measuring internal information of scattering medium |
JP3577335B2 (en) * | 1993-06-02 | 2004-10-13 | 浜松ホトニクス株式会社 | Scattering absorber measurement method and device |
US5421329A (en) * | 1994-04-01 | 1995-06-06 | Nellcor, Inc. | Pulse oximeter sensor optimized for low saturation |
US6662033B2 (en) | 1994-04-01 | 2003-12-09 | Nellcor Incorporated | Pulse oximeter and sensor optimized for low saturation |
JP3562847B2 (en) * | 1994-11-15 | 2004-09-08 | 謙 石原 | Hemoglobin concentration measuring device |
US5524617A (en) * | 1995-03-14 | 1996-06-11 | Nellcor, Incorporated | Isolated layer pulse oximetry |
IT1277391B1 (en) * | 1995-07-28 | 1997-11-10 | Romano Deghenghi | CYCLIC PEPTIDES ANALOGUE OF SOMATOSTATIN TO ACTIVITY INHIBITING THE GROWTH HORMONE |
AUPN740796A0 (en) * | 1996-01-04 | 1996-01-25 | Circuitry Systems Limited | Biomedical data collection apparatus |
AU719852B2 (en) * | 1996-01-04 | 2000-05-18 | Larkace Pty Ltd | Bioenergetic data collection apparatus |
ATE468068T1 (en) | 1998-07-04 | 2010-06-15 | Whitland Res Ltd | BLOODLESS MEASUREMENT OF ANALYTES FROM BLOOD |
AU5180499A (en) * | 1998-08-13 | 2000-03-06 | Whitland Research Limited | Optical device |
EP1121048A4 (en) | 1998-10-13 | 2003-06-25 | Somanetics Corp | Multi-channel non-invasive tissue oximeter |
CN101232843A (en) | 2005-09-13 | 2008-07-30 | 爱德华兹生命科学公司 | Continuous spectroscopic measurement of total hemoglobin |
JP5443075B2 (en) * | 2009-06-30 | 2014-03-19 | 株式会社日立製作所 | Game system, biological light measurement device |
JP5822444B2 (en) * | 2010-07-29 | 2015-11-24 | 株式会社島津製作所 | Light measuring device |
WO2012061584A2 (en) | 2010-11-03 | 2012-05-10 | University Of Washington Through Its Center For Commercialization | Deternimation of tissue oxygenation in vivo |
JP5238087B1 (en) | 2012-02-20 | 2013-07-17 | 浜松ホトニクス株式会社 | Concentration measuring device and concentration measuring method |
JP6006668B2 (en) * | 2013-03-29 | 2016-10-12 | 浜松ホトニクス株式会社 | Concentration measuring device and concentration measuring method |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4281645A (en) * | 1977-06-28 | 1981-08-04 | Duke University, Inc. | Method and apparatus for monitoring metabolism in body organs |
US4907876A (en) * | 1987-05-08 | 1990-03-13 | Hamamatsu Photonics Kabushiki Kaisha | Examination apparatus for measuring oxygenation in body organs |
US4807631A (en) * | 1987-10-09 | 1989-02-28 | Critikon, Inc. | Pulse oximetry system |
-
1992
- 1992-06-04 JP JP5500635A patent/JPH07500259A/en active Pending
- 1992-06-04 EP EP92913850A patent/EP0597875A4/en not_active Withdrawn
- 1992-06-04 WO PCT/US1992/004654 patent/WO1992021283A1/en not_active Application Discontinuation
- 1992-06-04 CA CA002110716A patent/CA2110716C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1992021283A1 (en) | 1992-12-10 |
EP0597875A4 (en) | 1995-02-08 |
JPH07500259A (en) | 1995-01-12 |
EP0597875A1 (en) | 1994-05-25 |
CA2110716A1 (en) | 1992-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5902235A (en) | Optical cerebral oximeter | |
CA2110716C (en) | Optical cerebral oximeter | |
CA2494030C (en) | Method for spectrophotometric blood oxygenation monitoring | |
Cheatle et al. | Near-infrared spectroscopy in peripheral vascular disease | |
US6456862B2 (en) | Method for non-invasive spectrophotometric blood oxygenation monitoring | |
US6421549B1 (en) | Adaptive calibration pulsed oximetry method and device | |
US8761851B2 (en) | Indicators for a spectrophotometric system | |
Zourabian et al. | Trans-abdominal monitoring of fetal arterial blood oxygenation using pulse oximetry | |
US6760609B2 (en) | Adaptive calibration pulsed oximetry method and device | |
US5803908A (en) | System for noninvasive hematocrit monitoring | |
EP0352923A1 (en) | Spectrophotometric apparatus and method for monitoring oxygen saturation | |
Bernardi et al. | Measurement of skin blood flow by laser-Doppler flowmetry | |
Liu et al. | Development of a miniaturized and modular probe for fNIRS instrument | |
US20090030296A1 (en) | Predictive oximetry model and method | |
US20150018651A1 (en) | Indicators for a spectrophotometric system | |
Yoon et al. | Robust design of finger probe in non-invasive total haemoglobin monitor | |
Kraitl et al. | Analysis of time series for non-invasive characterization of blood components and circulation patterns | |
McCormick et al. | Noninvasive measurement of regional cerebrovascular oxygen saturation in humans using optical spectroscopy | |
Buyanov et al. | Cerebral Oxygenation Response to Orthostatic Hypotension with Electroencephalography and Near Infrared Spectroscopy | |
Robinson et al. | In vivo performance of a visible wavelength optical sensor for monitoring intestinal perfusion and oxygenation | |
Vazquez-Jaccaud et al. | Transillumination waveform simulator for pulse oximetry | |
Levy et al. | The calibration and validation of a phase-modulated near-infrared cerebral oximeter | |
Noponen et al. | Near-infrared measurements of hemodynamic and oxygenation changes on the frontal cortex during breath holding, hyperventilation, and natural sleep | |
Chance | NIR spectroscopy of adult human brain: continuous-light and pulse-light spectroscopy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |